ArticleOncotarget2016
c-Myc deregulation induces mRNA capping enzyme dependency.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Analysis of genetic mutation characteristics in 40 Chinese patients with hepatocellular carcinoma.Genes & genomics · 2026Article
- RNMT-dependent RNA cap methylation in health and disease.The Biochemical journal · 2025Review
- Characterisation of RNA guanine-7 methyltransferase (RNMT) using a small molecule approach.The Biochemical journal · 2025Article
- eIF4E orchestrates mRNA processing, RNA export and translation to modify specific protein production.Nucleus (Austin, Tex.) · 2024Review
- METTL3 alters capping enzyme expression and its activity on ribosomal proteins.Scientific reports · 2024Article
- METTL3 alters capping enzyme expression and its activity on ribosomal proteins.bioRxiv : the preprint server for biology · 2023Article
- The RNA cap methyltransferases RNMT and CMTR1 co-ordinate gene expression during neural differentiation.Biochemical Society transactions · 2023Review
- E-box binding transcription factors in cancer.Frontiers in oncology · 2023Review
- MYC protein interactors in gene transcription and cancer.Nature reviews. Cancer · 2021Review
- To cap it all off, again: dynamic capping and recapping of coding and non-coding RNAs to control transcript fate and biological activity.Cell cycle (Georgetown, Tex.) · 2021Review
- Integrated requirement of non-specific and sequence-specific DNA binding in Myc-driven transcription.The EMBO journal · 2021Article
- Interplay of mRNA capping and transcription machineries.Bioscience reports · 2020Review
- Oncogenic PIK3CA mutations increase dependency on the mRNA cap methyltransferase, RNMT, in breast cancer cells.Open biology · 2019Article
- mRNA cap regulation in mammalian cell function and fate.Biochimica et biophysica acta. Gene regulatory mechanisms · 2019Review
- c-Myc co-ordinates mRNA cap methylation and ribosomal RNA production.The Biochemical journal · 2017Article
- Hydrogen peroxide yields mechanistic insights into human mRNA capping enzyme function.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
c-Myc is a potent driver of many human cancers. Since strategies for directly targeting c-Myc protein have had limited success, upstream regulators and downstream effectors of c-Myc are being investigated as alternatives for therapeutic intervention. c-Myc regulates transcription and formation of the mRNA cap, which is important for transcript maturation and translation. However, the direct mechanism by which c-Myc upregulates mRNA capping is unclear. mRNA cap formation initiates with the linkage of inverted guanosine via a triphosphate bridge to the first transcribed nucleotide, catalysed by mRNA capping enzyme (CE/RNGTT). Here we report that c-Myc increases the recruitment of catalytically active CE to RNA polymerase II and to its target genes. c-Myc-induced target gene expression, cell proliferation and cell transformation is highly dependent on CE, but only when c-Myc is deregulated. Cells retaining normal control of c-Myc expression are insensitive to repression of CE. c-Myc expression is also dependent on CE. Therefore, inhibiting CE provides an attractive route for selective therapeutic targeting of cancer cells which have acquired deregulated c-Myc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.